Theravance Biopharma (NASDAQ:TBPH) Posts Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Theravance Biopharma (NASDAQ:TBPH) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25), Yahoo Finance reports. Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. During the same period in the prior year, the firm earned ($0.28) EPS.

Theravance Biopharma Price Performance

NASDAQ:TBPH traded up $0.02 during trading hours on Wednesday, hitting $7.85. The company’s stock had a trading volume of 3,609,332 shares, compared to its average volume of 409,686. The company has a market capitalization of $381.77 million, a P/E ratio of -9.22 and a beta of 0.24. Theravance Biopharma has a twelve month low of $7.69 and a twelve month high of $11.71. The stock has a fifty day simple moving average of $9.05 and a 200-day simple moving average of $9.09.

Wall Street Analysts Forecast Growth

TBPH has been the topic of a number of recent analyst reports. StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. BTIG Research assumed coverage on Theravance Biopharma in a report on Friday, April 12th. They set a “buy” rating and a $21.00 price objective for the company. Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday. SVB Leerink cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price target for the company from $15.00 to $10.00 in a research note on Tuesday. Finally, HC Wainwright lowered their price objective on Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $13.75.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.